Legal & General Group’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.12M | Sell |
110,250
-20,973
| -16% | -$417K | ﹤0.01% | 1887 |
|
|
2025
Q4 | $2.17M | Sell |
131,223
-12,729
| -9% | -$215K | ﹤0.01% | 1938 |
|
|
2025
Q3 | $2.09M | Buy |
143,952
+12,197
| +9% | +$175K | ﹤0.01% | 1960 |
|
|
2025
Q2 | $1.84M | Sell |
131,755
-20,207
| -13% | -$284K | ﹤0.01% | 1995 |
|
|
2025
Q1 | $2.07M | Buy |
151,962
+2,449
| +2% | +$46.9K | ﹤0.01% | 1908 |
|
|
2024
Q4 | $3.05M | Buy |
149,513
+8,108
| +6% | +$208K | ﹤0.01% | 1808 |
|
|
2024
Q3 | $4.12M | Buy |
141,405
+12,059
| +9% | +$299K | ﹤0.01% | 1663 |
|
|
2024
Q2 | $3M | Buy |
129,346
+21,896
| +20% | +$420K | ﹤0.01% | 1766 |
|
|
2024
Q1 | $2.2M | Buy |
107,450
+737
| +0.7% | +$13.9K | ﹤0.01% | 1900 |
|
|
2023
Q4 | $2.29M | Buy |
106,713
+888
| +0.8% | +$17.6K | ﹤0.01% | 1880 |
|
|
2023
Q3 | $2.18M | Buy |
105,825
+933
| +0.9% | +$23.7K | ﹤0.01% | 1860 |
|
|
2023
Q2 | $3.1M | Buy |
104,892
+7,274
| +7% | +$205K | ﹤0.01% | 1713 |
|
|
2023
Q1 | $2.25M | Buy |
97,618
+2,603
| +3% | +$71.6K | ﹤0.01% | 1835 |
|
|
2022
Q4 | $2.64M | Buy |
95,015
+8,998
| +10% | +$268K | ﹤0.01% | 1742 |
|
|
2022
Q3 | $2.64M | Sell |
86,017
-486
| -0.6% | -$15.8K | ﹤0.01% | 1711 |
|
|
2022
Q2 | $2.55M | Buy |
86,503
+7,077
| +9% | +$185K | ﹤0.01% | 1763 |
|
|
2022
Q1 | $2.56M | Buy |
79,426
+455
| +0.6% | +$15.7K | ﹤0.01% | 1875 |
|
|
2021
Q4 | $3.52M | Buy |
78,971
+1,443
| +2% | +$68.4K | ﹤0.01% | 1761 |
|
|
2021
Q3 | $3.91M | Buy |
77,528
+15,284
| +25% | +$861K | ﹤0.01% | 1684 |
|
|
2021
Q2 | $4.88M | Buy |
62,244
+18,694
| +43% | +$1.16M | ﹤0.01% | 1543 |
|
|
2021
Q1 | $2.49M | Sell |
43,550
-1,347
| -3% | -$90.2K | ﹤0.01% | 1885 |
|
|
2020
Q4 | $3.76M | Buy |
44,897
+5,311
| +13% | +$321K | ﹤0.01% | 1612 |
|
|
2020
Q3 | $1.42M | Buy |
39,586
+4,832
| +14% | +$146K | ﹤0.01% | 1915 |
|
|
2020
Q2 | $840K | Buy |
34,754
+8,476
| +32% | +$199K | ﹤0.01% | 2034 |
|
|
2020
Q1 | $460K | Sell |
26,278
-1,381
| -5% | -$28.8K | ﹤0.01% | 2092 |
|
|
2019
Q4 | $482K | Buy |
27,659
+1,861
| +7% | +$31K | ﹤0.01% | 2226 |
|
|
2019
Q3 | $395K | Hold |
25,798
| – | – | ﹤0.01% | 2211 |
|
|
2019
Q2 | $536K | Buy |
25,798
+490
| +2% | +$11K | ﹤0.01% | 2131 |
|
|
2019
Q1 | $587K | Buy |
25,308
+16,670
| +193% | +$349K | ﹤0.01% | 2120 |
|
|
2018
Q4 | $179K | Buy |
8,638
+1,212
| +16% | +$22K | ﹤0.01% | 2332 |
|
|
2018
Q3 | $162K | Sell |
7,426
-6,554
| -47% | -$108K | ﹤0.01% | 2380 |
|
|
2018
Q2 | $213K | Sell |
13,980
-37,756
| -73% | -$711K | ﹤0.01% | 2283 |
|
|
2018
Q1 | $1.02M | Buy |
51,736
+51,681
| +93,965% | +$1.06M | ﹤0.01% | 1881 |
|
|
2017
Q4 | $1K | Buy |
+55
| New | +$988 | ﹤0.01% | 3280 |
|
Other funds holding DNLI
VCM
VPM
Legal & General Group's DNLI Position: Q1 2026 in Review
Legal & General Group reduced its Denali Therapeutics (DNLI) stake by 16% in Q1 2026, selling an estimated $417K and leaving 110,250 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1887.
Legal & General Group first reported a position in DNLI in Q4 2017 and has held it in 34 quarters since. The position peaked at $4.88M in Q2 2021. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.
- Legal & General Group held 110,250 shares of Denali Therapeutics worth $2.12M as of Q1 2026.
- Legal & General Group sold 20,973 Denali Therapeutics shares in Q1 2026, an estimated $417K.
- Denali Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #1887 holding.
- Legal & General Group first reported a position in Denali Therapeutics in Q4 2017 and has held it in 34 quarters since.
- Legal & General Group's Denali Therapeutics position peaked at $4.88M in Q2 2021.
- 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.
Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.